Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 11/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934947 | 0.99 | S1PR1 (0.58) | S1PR1S1PR3S1PR5CYP3A4CYP2C9 | |
| SCHEMBL2934951 | 0.99 | S1PR1 (0.58) | S1PR1S1PR3S1PR5CYP3A4CYP2C9 | |
| SCHEMBL2934948 | 0.93 | S1PR1 (0.56) | S1PR1S1PR3S1PR5CYP3A4CYP2C9 | |
| SCHEMBL2934772 | 0.91 | S1PR1 (0.56) | S1PR1S1PR3S1PR5CYP3A4CYP2C9 | |
| SCHEMBL2927101 | 0.91 | S1PR1 (0.57) | S1PR1S1PR3S1PR5KCNH2 | |
| SCHEMBL2934990 | 0.90 | S1PR1 (0.57) | S1PR1S1PR3S1PR5CYP3A4CYP2C9 | |
| SCHEMBL13488972 | 0.88 | S1PR1 (0.57) | S1PR1S1PR3S1PR5CYP3A4CYP2C9 | |
| SCHEMBL14180953 | 0.87 | S1PR1 (0.54) | S1PR1S1PR3S1PR5CYP3A4CYP2C9 | |
| SCHEMBL2933550 | 0.83 | S1PR1 (0.54) | S1PR1S1PR3S1PR5KCNH2 | |
| SCHEMBL2927103 | 0.80 | S1PR1 (0.56) | S1PR1S1PR3S1PR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091950-B1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | claimed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | claimed |
| EP-2091950-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | claimed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| EP-2091950-B1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-2091950-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.